logo/base Created with Sketch.

FibroScan® y Fast™ score: Game Changers en la estadificación de NAFLD y la evaluación de la respuesta al tratamiento

Presentación sólo en inglés

 

In this webinar, Dr. Alkhouri will review the latest clinical strategies for using FibroScan® VCTE, CAP and the FAST Score to risk stratify NAFLD-NASH patients and monitor therapeutic response during treatment.

About Dr. Alkhouri

Dr. Naim Alkhouri, M.D., is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX. Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute. Dr. Alkhouri has been published in over 160 publications and presents his work at both national and international medical conferences. Among many research awards,
Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. 
Dr. Alkhouri’s specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation.

Speaker

Naim Alkhouri
M.D., VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ
chevron ver la repetición